Illuminating cancer risks, without barriers

Genetic insights from the all-in-one personalized hereditary cancer risk assessment
Comprehensive, personalized answers – for better care

24% of women¹ have a concerning cancer family history

The only way to know what level of cancer screening and risk-reduction is appropriate is with a hereditary cancer test

53% of tested patients require an altered plan², with increased medical management options

Without a genetic result, possible outcomes include:
- Medical plan untailored to patient risk
- Underutilization of necessary screening modalities
- Delayed cancer diagnoses
- Lack of personalized treatment options

MyRisk® Hereditary Cancer Test with RiskScore®
Provides a personalized cancer risk and management guide for up to 100% of eligible patients

Genetic insights for ALL at-risk patients, regardless of ancestry
RiskScore® increases precision for patients of every ancestry

RiskScore estimates an individual patient’s 5-year and lifetime breast cancer risk based on medical history, family history, and genetic markers. Myriad was the first and only lab to make this precision answer available and accurate for patients of any ancestry.

Breast Cancer RiskScore®

Result

32.5% remaining lifetime risk for breast cancer
1.7% 5-year risk for breast cancer

Breast Cancer RiskScore Remaining lifetime risk

General Population

This Patient

20% Risk Threshold

13%

32.5%

More than a test – a management guide tailored to your patient

53% of patients are expected to have a medical management change2 with MyRisk® with RiskScore®

Management Options for a breast cancer risk estimate at or above the 20% threshold based on RiskScore® and/or the Tyrer-Cuzick model

<table>
<thead>
<tr>
<th>PROCEDURE</th>
<th>AGE TO BEGIN</th>
<th>FREQUENCY</th>
<th>RELATED TO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast awareness</td>
<td>Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness. 1</td>
<td>Individualized</td>
<td>RiskScore at or above the 20% threshold</td>
</tr>
<tr>
<td>Clinical encounter, including clinical breast exam, ongoing risk assessment and risk reduction counseling 2</td>
<td>At age identified as being at increased risk</td>
<td>Every 6 to 12 months</td>
<td>RiskScore at or above the 20% threshold</td>
</tr>
<tr>
<td>Mammography, with consideration of tomosynthesis 1</td>
<td>10 years younger than the earliest diagnosis in the family, but not younger than 30</td>
<td>Annually</td>
<td>RiskScore at or above the 20% threshold</td>
</tr>
<tr>
<td>Breast MRI with contrast 1</td>
<td>10 years younger than the earliest diagnosis in the family, but not younger than 25</td>
<td>Annually</td>
<td>RiskScore at or above the 20% threshold</td>
</tr>
</tbody>
</table>

Consider additional risk-reduction strategies. 1

## Patient case study

### Medical Management

<table>
<thead>
<tr>
<th>Test</th>
<th>Status</th>
<th>Other tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic test result</td>
<td>Negative</td>
<td>Tyrer-Cuzick: 19.4%</td>
</tr>
<tr>
<td>MyRisk® with RiskScore®</td>
<td></td>
<td>Tyrer-Cuzick: 19.4%</td>
</tr>
<tr>
<td>RiskScore</td>
<td></td>
<td>32.5%</td>
</tr>
</tbody>
</table>

### Other tests

- Clinical breast exam: ✔
- Breast awareness: ✔
- MRI: ✔
- Mammography: ✔
- Risk-reducing strategies: ✔

### Patient details:

- Age: 35
- Cancer family history: Aunt with breast cancer at 48
- Hereditary cancer test result: Negative

### Risk-reducing strategies

2. Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.
3. Myriad Internal Data Based on OBGYN & Primary Care setting. Last Updated 2023

### Making genetic insights affordable for everybody

Myriad Genetics’ financial assistance program takes into account each patient’s ability to pay, working with them directly to find the best option.

- 90% of patients are eligible for financial assistance
- 95% of private insurers have coverage for testing

---

*Case studies are illustrative.

©2023, Myriad Genetics, Inc. All rights reserved. ©2023 Myriad Genetics, Inc. All rights reserved. Myriad Genetics, MyRisk, RiskScore and their logos are either trademarks or registered trademarks of Myriad Genetics, Inc., and its subsidiaries in the United States and other jurisdictions. MGWhMRRPRB 0623